John C. Reed, EVP of Innovative Medicine and R&D at Johnson & Johnson, sold $20.4 million in JNJ shares across five open market transactions over the past year. His most recent sale occurred on February 17, 2026. These sales rank 665th among 11,678 insiders by total value, surpassing the average of $8.6 million per seller and 6.4 transactions. Reed made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 1349 | $0.00 | 12,007.0000 | 2,429,400,000 | 12.66% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Employee Stock Options (Right to Buy) | 29927 | $0.00 | 59,854.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Employee Stock Options (Right to Buy) | 21721 | $0.00 | 21,721.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | A | Restricted Share Units | 3546 | $0.00 | 3,546.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | A | Employee Stock Options (Right to Buy) | 49382 | $0.00 | 49,382.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 1847 | $0.00 | 3,692.0000 | 2,429,400,000 | 33.35% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 1349 | $0.00 | 1,349.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 2283 | $243.00 | 10,658.0000 | 2,429,400,000 | 17.64% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 29927 | $243.00 | 12,941.0000 | 2,429,400,000 | 69.81% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 29927 | $156.15 | 42,868.0000 | 2,429,400,000 | 231.26% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 21721 | $243.00 | 12,941.0000 | 2,429,400,000 | 62.67% | 0.00% |
| Feb. 17, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 21721 | $157.92 | 34,662.0000 | 2,429,400,000 | 167.85% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 528 | $243.45 | 12,941.0000 | 2,429,400,000 | 3.92% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 1847 | $0.00 | 13,469.0000 | 2,429,400,000 | 15.89% | 0.00% |
| Feb. 15, 2026 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 385 | $243.45 | 11,622.0000 | 2,429,400,000 | 3.21% | 0.00% |
| Oct. 17, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Employee Stock Options (Right to Buy) | 21721 | $157.92 | 43,442.0000 | 2,428,600,000 | 33.33% | 0.00% |
| Oct. 17, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 21721 | $157.92 | 32,379.0000 | 2,428,600,000 | 203.80% | 0.00% |
| Oct. 17, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 21721 | $192.71 | 10,658.0000 | 2,428,600,000 | 67.08% | 0.00% |
| July 17, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 19137 | $163.55 | 10,658.0000 | 2,429,400,000 | 64.23% | 0.00% |
| May 1, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 11002 | $156.31 | 29,795.0000 | 2,429,400,000 | 26.97% | 0.00% |
| May 1, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 25255 | $0.00 | 40,797.0000 | 2,429,400,000 | 162.50% | 0.00% |
| May 1, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 25255 | $0.00 | 25,255.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 15, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | A | Employee Stock Options (Right to Buy) | 89781 | $0.00 | 89,781.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | A | Restricted Share Units | 5539 | $0.00 | 5,539.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 18, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 385 | $156.15 | 15,542.0000 | 2,429,400,000 | 2.42% | 0.00% |
| Feb. 15, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 1350 | $0.00 | 15,927.0000 | 2,429,400,000 | 9.26% | 0.00% |
| Feb. 15, 2025 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 1350 | $0.00 | 2,698.0000 | 2,429,400,000 | 33.35% | 0.00% |
| May 1, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 25255 | $0.00 | 50,510.0000 | 2,560,400,000 | 33.33% | 0.00% |
| May 1, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 25255 | $0.00 | 25,561.0000 | 2,560,400,000 | 8253.27% | 0.00% |
| May 1, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 10984 | $144.59 | 14,577.0000 | 2,560,400,000 | 42.97% | 0.00% |
| May 1, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 22255 | $0.00 | 53,510.0000 | 2,560,400,000 | 29.37% | 0.00% |
| May 1, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 22255 | $0.00 | 22,561.0000 | 2,560,400,000 | 7272.88% | 0.00% |
| May 1, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 10984 | $144.59 | 11,577.0000 | 2,560,400,000 | 48.69% | 0.00% |
| Feb. 15, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | A | Employee Stock Options (Right to Buy) | 65163 | $0.00 | 65,163.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Innovative Medicine, R&D | A | Restricted Share Units | 4048 | $0.00 | 4,048.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| May 1, 2023 | JOHNSON & JOHNSON | $JNJ | REED JOHN C | EVP, Pharmaceuticals R&D | A | Restricted Share Units | 75765 | $0.00 | 75,765.0000 | 2,663,900,000 | 9999.99% | 0.00% |